{
    "2018-11-27": [
        [
            {
                "time": "2018-01-03",
                "original_text": "Zafgen (ZFGN) Plunges as FDA Puts Hold on Diabetes Drug Trial",
                "features": {
                    "keywords": [
                        "Zafgen",
                        "FDA",
                        "hold",
                        "diabetes",
                        "drug trial"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Lilly to Announce 2019 Financial Guidance, Highlight Late-Stage Pipeline Opportunities and Discuss Commercial Performance at Upcoming Investment Community Meeting",
                "features": {
                    "keywords": [
                        "Lilly",
                        "financial guidance",
                        "pipeline opportunities",
                        "commercial performance",
                        "investment community"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and established cardiovascular disease in new Expert Consensus Decision Pathway",
                "features": {
                    "keywords": [
                        "American College of Cardiology",
                        "empagliflozin",
                        "SGLT2 inhibitor",
                        "type 2 diabetes",
                        "cardiovascular disease"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}